To explore the therapeutic properties of zotarolimus and mTOR drugs for CRC, we examined tumor growth and various aspects related to tumor development, including apoptosis, inflammation, and metastasis, with the objective of expanding the number of drugs available for CRC treatment. This evidence concerns the gene MTOR and colorectal carcinoma.